Eye doctors fighting Genentech decision

The California Academy of Eye Physicians and Surgeons has issued a call for South San Francisco’s Genentech Inc. (DNA) to reverse its decision to halt sales of its drug Avastin to compounding pharmacies effective November 30, 2007.

The group is asking the California Medical Association and possibly the American Medical Association to take a stand on the issue as well.

Opthalmologists have been using Avastin, a drug currently only approved for cancer, to treat age-related macular degeneration, a common eye disease. Because only a small portion of a standard dose is needed for eye treatment, eye doctors have generally purchased the drug from compounding pharmacies, which repackage it in smaller doses.

Genentech, however, also sells a similar but much more expensive drug, Lucentis, which according to information provided by the physicians sells for approximately $2,000 a dose versus approximately $40 a dose for Avastin.

Just Posted

Community-led efforts to monitor air quality in Bayview, Eastern neighborhoods gain traction

San Francisco community groups are working to install high-quality sensors in the… Continue reading

Homeless shelter opponents use attack as ammunition in fight against city

A week after being attacked outside her condo building near the Embarcadero,… Continue reading

Fire department drill finds traffic around Chase Arena could slow response time

For years, some have feared the future home of the Golden State… Continue reading

Did Scoot ‘redline’ SF neighborhoods? Chinatown group says ‘we asked for it’

The talk of the transportation world is a Los Angeles Times story… Continue reading

New hires solve SF school crossing guard shortage — for now

San Francisco has gone on a school crossing guard-hiring binge, hoping to… Continue reading

Most Read